Sanofi

Massachusetts Institute of Technology

Horst Blum

Rajeev J Ram

Shireen Goh

Michelangelo Canzoneri

Kevin Shao-Kwan Lee

Hans Matter

Otmar Klingler

Christian Lange

Béatrice Cameron

Carsten Corvey

Tarik Dabdoubi

Nicolas Baurin

Andreas Lindenschmidt

David Papin

Control of volume in bioreactors and associated systems is generally described. Feeding and/or sampling strategies can be employed, in some embodiments, such that the working volume within the bioreactor remains substantially constant.

Small volume bioreactors with substantially constant working volumes and associated systems and methods

Control of humidity in chemical reactors, and associated systems and methods, are generally described. In certain embodiments, the humidity within gas transport conduits and chambers can be controlled to inhibit unwanted condensation within gas transport pathways. By inhibiting condensation within gas transport pathways, clogging of such pathways can be limited (or eliminated) such that transport of gas can be more easily and controllably achieved. In addition, strategies for purging condensed liquid from chemical reactor systems are also described.

Humidity control in chemical reactors

The present invention relates to a peptide or peptide complex binding to &#x3b1;2 integrin, to one or more nucleic acid(s) coding for the peptide or peptide complex, a recombinant cell producing the peptide or peptide complex, a method for producing the peptide or peptide complex, a pharmaceutical composition comprising the peptide or peptide complex or the nucleic acid(s) for use as a medicament, a method for detecting &#x3b1;2 integrin and a screening method.

Peptide or peptide complex binding to ALPHA2 integrin and methods and uses involving the same

The present invention relates to compounds of the Formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, X1, X2, X3 and X4 have the meanings indicated in the claims, and which are valuable pharmacologically active compounds. They are reversible inhibitors of the interaction between the plasma protein von Willebrand factor (vWF) and the blood platelet receptor glycoprotein Ib-IX-V complex (GPIb), and are suitable, for example, for the therapy and prophylaxis of athero-thrombotic diseases. The invention furthermore relates to processes for the preparation of compounds of the Formula (I), their use, in particular as active ingredients in medicaments, and pharmaceutical compositions comprising them. 

Cyclic peptides, their preparation and their use as inhibitors of the platelet adhesion

Growing community of inventors

Kriftel, Germany

Horst Blum